Emyria Ltd (ASX:EMD) CEO Michael Winlo sits down with Proactive’s Jonathan Jackson to discuss significant advancements in the company's mental health initiatives. Emyria recently opened the Empax Centre, a cutting-edge facility aimed at enhancing mental health treatments, including MDMA-assisted therapy for PTSD. Emyria’s ambitious vision is showcased by this centre, targeting care gaps in resistant PTSD, with sights set on operational profitability and global expansion. Winlo discusses how the technology employed at the Empax Centre enhances patient care as well as Emyria’s plans to broaden its therapeutic offerings. Significant progress has also been made with the expansion of Emyria’s authorised prescriber team. The addition of a second psychiatrist as an authorised prescriber underlines Emyria’s commitment to advancing mental health care, aligning with its expansion efforts. Emyria is also collaborating with charity Reach Wellness and this partnership signifies a strategic step towards validating Emyria’s MDMA-assisted therapy model, aiming to improve PTSD treatment for first responders. This collaboration, backed by significant fundraising, is pivotal for demonstrating the model’s safety, effectiveness and scalability.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
